Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scientists from the Department of Oncology have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

One of the problems we face in killing tumours is that the tumours often recruit healthy cells to help them grow and to protect them from attack.  In this case tumours often recruit fibroblasts to help them shape their local environment and protect them from the immune system.

Dr Fisher and Dr Freedman have engineered a virus so that it both attacks tumour cells directly, and also attacks the fibroblasts, which are supporting the tumour.  The virus attacks the tumour cells and in doing so forces, the tumour cells to make a protein, which binds to fibroblasts and sticks them to and immune cell called a T-cell.  The T-cells are triggered to attack and destroy the fibroblasts helping to undermine the support that the tumour is replying on.

People have tried to attack fibroblast before, but this often causes widespread destruction of fibroblasts, whereas this work targets the tumour-associated fibroblasts which are supporting the tumour.

Read more (University of Oxford website)

Similar stories

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Subashan Vadibeler wins 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.